Dr. Francois Nader is an accomplished leader in the life sciences sector. He currently serves as Chairman of GENIE Lifesciences, Board Director for Moderna (MRNA) and RING Therapeutics, and is a Senior Advisor at Blackstone Life Sciences. Additionally, he is the Chairman of the Jesra Foundation and BioLink.org, and he serves on the Board of Trustees for the Lebanese American University.
Dr. Nader served as Chairman of BioNJ, Acceleron Pharma (acquired by Merck), Prevail Therapeutics (acquired by Lilly), Neurvati Neurosciences and BenevolentAI. In addition, he has held Board Director positions at Acceleron Pharma (acquired by Merck), Prevail Therapeutics (acquired by Lilly), Alexion (acquired by AstraZeneca), Clementia (acquired by IPSEN), Advanced Accelerator Applications (acquired by Novartis), Baxalta (acquired by Shire), and Noven (acquired by Hisamitsu).
He has been recognized for his contributions with numerous awards, including the Lebanese National Order of Merit, the EY National Life Science Entrepreneur of the Year®, and the Ellis Island Medal of Honor.
Before his current roles, Dr. Nader served as the CEO of NPS Pharma, where he successfully transformed the company into a global biotechnology powerhouse, providing breakthrough treatments for rare diseases. The company was acquired by Shire. He also held a venture partner position at Care Capital and various leadership roles at Aventis, Hoechst Marion Roussel, and Pasteur Vaccins.
Dr. Nader holds a French Doctorate in Medicine from St. Joseph University in Lebanon and a Physician Executive MBA from the University of Tennessee.
